Lightlake Therapeutics (LLTP) 7.4500 $LLTP Lightlake

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lightlake Therapeutics (LLTP) 7.4500 $LLTP

Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone
PR Newswire - Wed Jun 03, 8:34AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis.

Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study
PR Newswire - Wed Apr 22, 8:00AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited ("Adapt" , Lightlake's partner for treating opioid overdose with intranasal naloxone, successfully completed a clinical study of intranasal naloxone.

Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
PR Newswire Europe - Mon Mar 09, 8:01AM CDT
- Lightlake invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation.

5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at VirtualInvestorConferences.com
PR Newswire - Tue Mar 03, 7:30AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
RDHL: 18.46 (+0.11), ONVO: 3.82 (+0.26)

Lightlake Therapeutics Inc. Announces Fast Track Designation From The United States Food And Drug Administration For Intranasal Naloxone Treatment To Reverse Opioid Overdose
PR Newswire - Tue Feb 17, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has received Fast Track designation by the United States Food and Drug Administration ("FDA" .

Lightlake Therapeutics Inc. Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs
PR Newswire - Mon Feb 09, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Arvind Agrawal has joined Lightlake as Executive Vice President, Medical Affairs, effective January 2015.

LightLake Therapeutics teams up with Adapt Pharma
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 9:26AM CST


Lightlake Therapeutics Inc. Announces Licensing Deal With Adapt Pharma Limited Subsidiary
PR Newswire - Tue Dec 16, 7:30AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has entered into a license agreement with Adapt Pharma Operations Limited ("Adapt" , a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company ("Adapt Pharma" . Pursuant to the agreement Adapt has received from Lightlake a global license to develop and commercialize Lightlake's intranasal naloxone opioid overdose reversal treatment. In exchange for licensing its treatment to Adapt, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.

Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)
PR Newswire - Thu Dec 04, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for opioid overdose.

Drug Addiction - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44hwmz/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Gilead Sciences, Inc. - Aphios Corporation - Teva Pharmaceutical Industries Limited - Addex Therapeutics Ltd - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - Rottapharm SpA - Omeros Corporation - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Lightlake Therapeutics Inc. - SK Biopharmaceuticals Co., Ltd. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/44..._addiction
GILD: 113.74 (+0.38), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)

Lightlake Therapeutics Inc. Announces Closing Of Investments In Two Products
PR Newswire - Thu Oct 02, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has closed on investments totaling $1,000,000. The investments were made by an investor in exchange for interests in two different Lightlake products.

Global Binge Eating Disorder Therapeutics Pipeline Review, H2 2014 Report - 5 Companies & 5 Drug Profiles
M2 - Wed Sep 10, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6jpp4g/binge_eating) has announced the addition of the "Binge Eating Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Binge Eating Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Teva Pharmaceutical Industries Limited - Shire Plc - Omeros Corporation - Heptares Therapeutics Ltd. - Lightlake Therapeutics Inc. Drug Profiles - armodafinil - lisdexamfetamine dimesylate - LT-12 - OMS-527 - Small Molecule Targeting Orexin 1 For more information visit http://www.researchandmarkets.com/research/6j...nge_eating
SHPG: 250.34 (+7.35), TEVA: 61.38 (-0.75), OMER: 17.33 (+0.29)

Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading